Studies in any language, from any country, and on any date were included
Decreased muscle mass: Rapid weight loss (and not necessarily the GLP-1 itself) can also potentially cause loss of muscle mass
[1] [2] Administered as a once-weekly subcutaneous injection, semaglutide works by enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying
That does not prove retatrutide causes cancer
The additional glucagon receptor activity in retatrutide produces greater weight loss and more dramatic liver fat reduction
Today, Im excited to share a recap of what this has meant for our membersthrough the lens of our largest-ever internal analysis on how engagement with Nooms GLP-1 Companion app is associated with success on GLP-1s, as well as how key product investments we made last year have increased the stickiness of our already highly engaging digital experience